Britannia Pharmaceuticals Ltd. focuses on developing innovative, patient-centric therapies aimed at improving the management of long-term neurological conditions, particularly Parkinson's disease, schizophrenia, and nephrology. The company emphasizes the importance of clinical trials, funding research initiatives that are designed to optimize treatment programs and enhance the quality of life for patients. Their commitment to innovation is reflected in their collaboration with specialist focus groups and their dedication to conducting ethical, high-quality clinical research.

In addition to their clinical trials, Britannia Pharmaceuticals supports Investigator Initiated Research (IIR), which allows external investigators to conduct independent scientific investigations relevant to the company's therapeutic areas. This approach not only fosters innovation but also ensures that the research addresses significant medical and scientific questions. By investing in both clinical trials and IIR, Britannia Pharmaceuticals aims to provide comprehensive support for patients, their families, and healthcare professionals, thereby enhancing the overall treatment landscape for neurological conditions.

United Kingdom

Britannia Pharmaceuticals, part of the STADA Arzneimittel AG group of companies, is a UK based pharmaceutical company specialising in the neurology market.

Britannia focuses on innovative products for chronic and serious medical conditions, and in particular, the treatment of Parkinson’s disease. We are highly committed to improving the quality of life for People with Parkinson's disease.

Britannia Pharmaceuticals Ltd

Company Details